What to expect in 2024: important health economics and outcomes research (HEOR) trends

Graphical Abstract

Transparency

Declaration of funding

No funding was received to produce this article.

Declaration of financial/other relationships

IA and KKCL are the Editors in Chief of the Journal of Medical Economics. MH is the Editor in Chief of the Expert Review of Pharmacoeconomics and Outcome Research. He has received research grant through institution from Radius Health and Angelini Pharma, consulting fee from UCB, lecture fees from Mylan Pharmaceuticals and IBSA (paid to institution) and served as grant advisor for Pfizer (paid to institution). LC is the Editor in Chief of Current Medical Research and Opinion. In addition served as Editor in Chief of the International Journal of Clinical Practice, through end 2019 and is the current Topic Editor for Psychiatry for Clinical Therapeutics; serves as a consultant to AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, BioXcel, Boehringer Ingelheim, Cadent Therapeutics, Cerevel, Clinilabs, COMPASS, Eisai, Enteris BioPharma, HLS Therapeutics, Idorsia, INmune Bio, Impel, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Lyndra, Medavante-ProPhase, Marvin, Merck, Mitsubishi-Tanabe Pharma, Neurocrine, Neurelis, Novartis, Noven, Otsuka, Ovid, Praxis, Recordati, Relmada, Reviva, Sage, Sunovion, Supernus, Teva, University of Arizona, Vanda, and one-off ad hoc consulting for individuals/entities conducting marketing, commercial, or scientific scoping research; speaker for AbbVie/Allergan, Acadia, Alkermes, Angelini, Axsome, BioXcel, Eisai, Idorsia, Intra-Cellular Therapies, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Recordati, Sage, Sunovion, Takeda, Teva, and CME activities organized by medical education companies such as Medscape, NACCME, NEI, Vindico, and Universities and Professional Organizations/Societies; owns stocks (small number of shares of common stock) in Bristol-Myers Squibb, Eli Lilly, J & J, Merck, Pfizer purchased > 10 years ago, and stock options in Reviva. GLC is the Editor in Chief of ClinicoEconomics and Outcomes Research Journal. He has received, in the last three years, research grant through institution from: Abbott, Abbvie, Alfasigma, Almirall, Astrazeneca, Beigene, Biogen, Boehringer Ingelheim, Corza, Diasorin, Ferring, Galapagos, Gedeon Richter, Gene Predicts, Gerot Lannach, Ipsen, Leopharma, Menarini, Merck, Norgine, Novo Nordisk, Pfizer, Roche, Sandoz, Sanofi, Servier, Sobi and Teva; lecture fees from: DocGenerici, Novartis, Pfizer, Sandoz and Teva

Acknowledgements

Kelly Soldavin helped with proofing and formatting of the article.

Additional information

Notes on contributors

Ivo Abraham

Ivo Abraham is a Professor of Pharmacy, Medicine, and Clinical Translational Sciences at the University of Arizona and is also EIC of the Journal of Medical Economics. His knowledge and experience of the HEOR field is extensive and he has particular interests in clinical outcomes and effectiveness research as well as value appraisal from molecules to models of care. He has (co-)authored 500+ articles and 80+ chapters, and has (co-)edited 50+ books, monographs, and journal issues. His group was among the first to recognize the economic importance of biosimilars in terms of health equity and access to care, and he writes a column for the AJMC Center for Biosimilars. He has been affiliated with universities in the US, Europe, and Asia.

Mickael Hiligsmann

Mickael Hiligsmann is Associate Professor in Health Economics and Health Technology Assessment at Maastricht University, the Netherlands, and is also EIC of Expert Review of Pharmacoeconomics & Outcomes Research. He holds two PhD degrees from Maastricht University and the University of Liège, a master in Public Health and a master in Economics. His research expertise and interest includes health technology evaluation (such as cost-effectiveness analyses, decision-analytic modelling, quality of life), the elicitation of preferences in health care, and medication adherence and patient involvement. He has been co-promotor of about 25 PhD students and is senior lecturer in HTA and health economic courses. He is currently author of about 275 peer-reviewed articles (with about 50 as first-author). He is the coordinator of the Maastricht Health Economics and Technology Assessment center.

Kenneth K. C. Lee

Kenneth K. C. Lee is Professor of Health Economics at Taylor’s University Malaysia. Previously he had held senior academic positions in Hong Kong and the UK. He has been EIC of JME since 2006. His area of research interest is healthcare evaluation at both micro and macro levels. Over the years, he has worked on research projects in collaboration with different clinical specialities including cardiology, dematology, gastroenterology, infectious diseases, oncology, public health and psychiatry. He served in a number of important positions in the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) including member of the Board of Directors and Co-editor in Chief of Value in Health Regional Issue. He has published extensively in international peer-reviewed journals with a few high-impact articles that had led to changes of international clinical management guidelines.

Leslie Citrome

Leslie Citrome is clinical professor of psychiatry and behavioral sciences at New York Medical College in Valhalla, New York, and Immediate Past-President of the American Society of Clinical Psychopharmacology, and a member of the Board of Directors of the World Association of Medical Editors. Dr. Citrome is a frequent lecturer on the quantitative assessment of clinical trial results, including the metrics of number needed to treat and number needed to harm. His main interests include schizophrenia, bipolar disorder, and major depressive disorder. He is author or coauthor of over 600 research reports, reviews, and chapters in the scientific literature. In 2019 he received the New York Medical College Faculty Author Award for “First Authorship Who Published in the Most Open Access Journals (Web of Science),” He has a private practice in psychiatry in Pomona, New York and is a volunteer consultant to the Assertive Community Treatment team/Mental Health Association of Rockland County.

Giorgio L. Colombo

Giorgio L. Colombo is an adjunct Professor at the University of Pavia - School of Pharmacy, and brings to his work a notable combination of academic theory and analytical practice. His experience in independent consultancy has seen him perform technological assessments and economic evaluations for pharmaceutical companies and Italian governmental authorities alike, while maintaining a highly active research portfolio. Much of his recent research has focused on the economic evaluations of Drugs and Medical Device, showcasing his ability to bring together theoretical models with their social and business applications. Since graduating from the Catholic University of Milan, Professor Colombo has authored or co-authored about 220 scientific papers and three books in the fields of health economics and pharmacoeconomics research, as well as sitting on the editorial boards of several scientific peer review journals.